The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Gordon, Kenneth
One or more keywords matched the following items that are connected to Gordon, Kenneth
Item TypeName
Concept Adjuvants, Immunologic
Concept Adrenal Cortex Hormones
Concept Antigens, Differentiation
Concept Anti-Inflammatory Agents, Non-Steroidal
Concept Carbon Dioxide
Concept Epitopes
Concept Anthralin
Concept Antibodies, Monoclonal
Concept Anti-Inflammatory Agents
Concept Histocompatibility Antigens Class II
Concept Autoantibodies
Concept Biological Products
Concept Etretinate
Concept Clonazepam
Concept Coal Tar
Concept C-Reactive Protein
Concept Collagen
Concept Dermatologic Agents
Concept Drug Synergism
Concept Immunosuppressive Agents
Concept Interleukin-2
Concept Interleukins
Concept Drug Carriers
Concept Immunologic Factors
Concept Drug Resistance
Concept Drug Therapy, Combination
Concept Fluoxetine
Concept Heterocyclic Compounds
Concept Dose-Response Relationship, Drug
Concept Drug Combinations
Concept Liposomes
Concept Keratolytic Agents
Concept Membrane Glycoproteins
Concept Nerve Tissue Proteins
Concept Methotrexate
Concept Peptide Fragments
Concept Nicotinic Acids
Concept Ovalbumin
Concept Immunoglobulin G
Concept Interferon-gamma
Concept Retinoids
Concept Thalidomide
Concept Interferon Type I
Concept United States Food and Drug Administration
Concept Tumor Necrosis Factor-alpha
Concept Acitretin
Concept Drug Design
Concept Isotretinoin
Concept CD11 Antigens
Concept Antibodies, Blocking
Concept Transforming Growth Factor beta
Concept Cell Adhesion Molecules
Concept Antigens, CD
Concept Adverse Drug Reaction Reporting Systems
Concept Drug Approval
Concept Drug Delivery Systems
Concept Tacrolimus
Concept Safety Management
Concept Interferon-alpha
Concept B7-1 Antigen
Concept Receptors, Tumor Necrosis Factor
Concept Myelin Proteolipid Protein
Concept Interleukin-12
Concept GABA Modulators
Concept Antirheumatic Agents
Concept Receptors, Interleukin-17
Concept Interleukin-23
Concept Immunoconjugates
Concept Phosphodiesterase 4 Inhibitors
Concept Piperidines
Concept Pyrimidines
Concept Recombinant Proteins
Concept Janus Kinase 3
Concept Pyrroles
Concept Interleukin-23 Subunit p19
Concept RNA, Messenger
Concept Sunscreening Agents
Concept Tetanus Toxoid
Concept Antibodies, Monoclonal, Humanized
Concept CTLA-4 Antigen
Concept Vitamin D
Concept Cyclosporine
Concept Drug Monitoring
Concept CD2 Antigens
Concept Botulinum Toxins, Type A
Concept Skin, Artificial
Concept Interleukin-17
Concept B7-2 Antigen
Concept Biosimilar Pharmaceuticals
Concept Antibodies, Antinuclear
Concept Drug Eruptions
Concept Doxorubicin
Concept Drug Administration Schedule
Concept Injections
Concept Recombinant Fusion Proteins
Concept Cytokines
Concept Anticarcinogenic Agents
Concept Antidepressive Agents, Second-Generation
Concept Macrolides
Concept Protein Kinase Inhibitors
Concept TYK2 Kinase
Concept Drug Substitution
Academic Article Comparative tolerability of systemic treatments for plaque-type psoriasis.
Academic Article Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
Academic Article Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Academic Article The immunology of psoriasis and biologic immunotherapy.
Academic Article A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Academic Article Duration of remission of biologic agents for chronic plaque psoriasis.
Academic Article Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Academic Article From laboratory to clinic: rationale for biologic therapy.
Academic Article Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Academic Article Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Academic Article Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Academic Article Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Academic Article Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Academic Article An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Academic Article Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul.
Academic Article Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
Academic Article Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Academic Article Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Academic Article Evolution of biologic therapies for the treatment of psoriasis.
Academic Article Remittive effects of intramuscular alefacept in psoriasis.
Academic Article Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Academic Article Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Academic Article Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
Academic Article Unmet needs in the treatment of psoriasis.
Academic Article A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Academic Article Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Academic Article A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Academic Article Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Academic Article Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Academic Article Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.
Academic Article In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model.
Academic Article Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Academic Article Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Academic Article Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
Academic Article Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
Academic Article Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Academic Article Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine.
Academic Article Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Academic Article Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Academic Article Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Academic Article Safety of the new macrolide immunomodulators.
Academic Article Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Academic Article Practical Strategies for Optimizing Management of Psoriasis.
Academic Article Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Academic Article Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Academic Article Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Academic Article Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Academic Article Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Academic Article Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Academic Article Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Academic Article Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Academic Article Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
Academic Article Defining drug-free remission of skin disease in patients with plaque psoriasis.
Academic Article Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.
Academic Article Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Academic Article A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Academic Article Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Academic Article Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Academic Article Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Academic Article Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
Academic Article Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Academic Article Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Academic Article Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Concept Drug-Related Side Effects and Adverse Reactions
Concept Calcineurin Inhibitors
Academic Article Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Academic Article Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Academic Article The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Academic Article Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Search Criteria
  • Drug
  • Safety